Hormone drug linked to increased prevalence of male genital disorder (pp 1081, 1102)March 27, 2002Results of a Dutch study in this week’s issue of THE LANCET highlight how a male genital disorder could be more common among boys born to mothers who were prenatally exposed to a synthetic hormone withdrawn in the late 1970s. The drug diethylstilbestrol (DES) was previously prescribed to prevent spontaneous abortion and preterm delivery. DES was withdrawn in the 1970s when it became clear that it was associated with vaginal cancer and fertility disorders in women who were exposed to the drug prenatally. Flora Van Leeuwen and colleagues from The Netherlands Cancer Institute, Amsterdam, Netherlands, aimed to establish the risk of hypospadias (a birth defect in boys where the urethral opening occurs on the underside of the penis or the scrotum) in sons of women who were prenatally exposed to DES. The investigators did a population study of around 8900 sons of over 16,000 women with fertility problems in The Netherlands. Mothers of 205 boys reported prenatal DES exposure. Four of these children were reported to have hypospadias. In the remaining 8729 children, only eight cases of hypospadias were reported, indicating that hypospadias was more than 20 times as common in boys whose mothers were exposed to DES. In an accompanying Commentary (p 1081), Sonia Hern'ˇndez-D'az from Boston University School of Public Health, USA, concludes: “Although diethylstilbestrol is no longer used, research on exposure to this drug may be relevant to current concerns about exposures to weaker oestrogens such as synthetic hormones present in oral contraceptives, phyto-oestrogens in the diet, or certain pesticides or solvents. Knowledge gained from the diethylstilbestrol debacle should be used to guide research on the possible risks associated with oestrogens that are being encountered by current generations.” Lancet |
|||||||||||||||||||||
| Related Estrogen Current Events and Estrogen News Articles Menopause-cardiology consensus statement on cardiovascular disease and on HRT A menopause-cardiology consensus statement has called for direct action to prevent cardiovascular disease (CVD) in menopausal women. The statement also concludes that there is little evidence of increased CVD risk in taking HRT. Heart and bone damage from low vitamin D tied to declines in sex hormones Researchers at Johns Hopkins are reporting what is believed to be the first conclusive evidence in men that the long-term ill effects of vitamin D deficiency are amplified by lower levels of the key sex hormone estrogen, but not testosterone. Fertility procedures need not delay breast cancer treatment for younger women A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion. Coffee break: Compound brewing new research in colon, breast cancer A compound in coffee has been found to be estrogenic in studies by Texas AgriLife Research scientists. Mayo researchers find robotic repair for vaginal prolapse has significant benefits New Mayo Clinic research has found that robotic surgery for vaginal prolapse dramatically reduces patient hospital stay and recovery time. Estrogen therapy likely must be given soon after menopause to provide stroke protection For estrogen replacement to provide stroke protection, it likely must be given soon after levels drop because of menopause or surgical removal of the ovaries, scientists report in the Journal of Neuroscience. Oral contraceptives may benefit women with asthma New research shows that during natural menstrual cycles, women with asthma who were not taking oral contraceptives (OC) had lower exhaled nitric oxide levels (eNO), a marker of airway inflammation associated with asthma, than women who were taking OC. Study shows hormone replacement therapy decreases mortality in younger postmenopausal woman Hormone replacement therapy (HRT) to treat menopausal estrogen deficiency has been in widespread use for over 60 years. Several observational studies over the years showed that HRT use by younger postmenopausal women was associated with a significant reduction in total mortality; available evidence supported the routine use of HRT to increase longevity in postmenopausal women. Hormone mix could cut breast cancer risk and treat symptoms of menopause The right combination of estrogen and a selective estrogen receptor modulator (SERM), which blocks the effects of estrogen in breast tissue, could relieve menopause symptoms and cut breast cancer risk. Breast tenderness during hormone replacement therapy linked to elevated cancer risk Women who developed new-onset breast tenderness after starting estrogen plus progestin hormone replacement therapy were at significantly higher risk for developing breast cancer than women on the combination therapy who didn't experience such tenderness, according to a new UCLA study. More Estrogen Current Events and Estrogen News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||